Mayo researchers explore issues related to multiple myeloma treatment

October 07, 2008

Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.

Outpatient vs. Inpatient Stem Cell Transplants

Since the 1990s, autologous stem cell transplant (ASCT) has become a standard treatment for many patients with MM. This treatment involves using high-dose chemotherapy along with transfusion of previously collected immature blood cells (stem cells) to replace diseased or damaged marrow. While ASCT often provides an effective method of controlling MM, hospitalized patients receiving this treatment are at increased risks for complications such as hospital-acquired infections, some of which are potentially fatal. In addition, the hospital care necessary to treat these complications can be costly.

In a brief report, Mayo researchers led by Mayo Clinic hematologist Morie Gertz, M.D., share study data that demonstrates the benefits of offering stem cell transplantation for MM patients in an outpatient setting. In this study, the Mayo research team followed 716 patients undergoing stem cell transplant for MM at Mayo Clinic from Jan. 1, 2000 through Oct. 31, 2007.

Not all of the MM patients studied were eligible for outpatient treatments, and some required hospitalization after ASCT began due to complications. Of the 716 BMT patients studied, 278 patients (39 percent) completed the transplant procedure as outpatients. The Mayo researchers noted that patients who received this care as outpatients had a high survival rate (99 percent at 100 days). And among those patients who began the treatment as outpatients but required some hospital care, the median hospitalization period was only four days.

"Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates," writes Dr. Gertz.

Other authors on this article include Stephen Ansell, M.D., Ph.D.; David Dingli, M.D., Ph.D.; Angela Dispenzieri, M.D.; Francis Buadi, M.D.; Michelle Elliott, M.D.; Dennis Gastineau, M.D.; Suzanne Hayman, M.D.; William Hogan, M.B.B.CH.; David Inwards, M.D.; Patrick Johnston, M.D., Ph.D.; Shaji Kumar, M.D.; Martha Lacy, M.D.; Ivana Micallef, M.D.; Luis Porrata, M.D.; Barbara Schafer and Mark Litzow, M.D., from Mayo Clinic's Division of Hematology; Nelson Leung, M.D., from Mayo Clinic's Division of Nephrology and Hypertension; and Robert Wolf, Ph.D., from Mayo Clinic's Hospital Pharmacy Services.

Cure vs. Control

In a related commentary, Mayo hematologist S. Vincent Rajkumar, M.D., discusses the need to re-examine the goals of clinical research and treatment for patients with MM. Given that MM is generally considered to be incurable, Dr. Rajkumar poses two important questions about treatment goals:

"Should we treat patients - with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality of life will be substantial? Or should we address myeloma as a chronic incurable condition with the goal of disease control, using the least toxic regimens, emphasizing a balance between efficacy and quality of life -?"

Dr. Rajkumar explains that for decades, this "cure vs. control" debate was not necessary because it was assumed that a cure was unattainable. However, since the 1990s, several new effective combination treatments have emerged and produced impressive results. While these advances are encouraging, Dr. Rajkumar advises that treatment decisions must still take into account patients' needs, goals and attitudes toward overall survival vs. quality of life.

"Although cure is the ultimate goal of our long-term research, we need more data from randomized trials before resorting to highly intense therapy that is more toxic and unlikely to lead to a cure outside the setting of a clinical trial."

Mayo Clinic

100 Questions and Answers About Myeloma (100 Questions & Answers about . . .)
by Asad Bashey (Author), Rafat Abonour (Author), James W. Huston (Author)

Whether you are a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor s and patient s views, 100 Questions & Answers About Myeloma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring insider advice from an actual patient, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J Heller (Author)

A comprehensive handbook and guide in easy to understand terms dealing with Multiple Myeloma; the disease, treatments, medications, lifestyle changes, and resources. Written by a non-medical author and based upon personal experiences. Updated annually.

My Bout with Multiple Myeloma
by Dennis Dinger (Author)

In 2008, the author was diagnosed with Multiple Myeloma, which is a blood plasma cancer. This book chronicles the author's battle - to include the times prior to diagnosis, the diagnosis itself, the treatments (four cycles of chemotherapy followed by one high dose cycle and an autologous stem cell transplant), and the recuperation period following all treatments. Since 2009, the cancer has been in complete remission. In this book, the author includes descriptions of most of the procedures to which he was subject, and he gives helpful hints and suggestions to others who may have to deal with this or other cancers. The book was written for those who have been similarly diagnosed, as well as for their family members and friends who may be called upon to support their loved ones through...

Medifocus Guidebook on: Multiple Myeloma
by Inc. Medifocus.com (Author), Elliot Jacob PhD. (Editor)

The MediFocus Guidebook on Multiple Myeloma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Multiple Myeloma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Multiple Myeloma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support...

What You Need To Know About: Multiple Myeloma

This booklet is about multiple myeloma, a cancer that starts in plasma cells, a type of white blood cell. It's also called plasma cell myeloma. Each year in the United States, about 20,000 people learn they have this disease.

This booklet tells about diagnosis, treatment options, and tests the doctor may give you during follow-up visits. It also tells about supportive care before, during, or after treatment. Learning about the medical care for multiple myeloma can help you take an active part in making choices about your care.

Multiple Myeloma (Emerging Cancer Therapeutics) (Emerging Concepts Therapeutics) (Emerging Cancer Therapeutics V1 I2)
by Shaji Kumar MD (Editor), Jame Abraham MD FACP (Editor)

The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, Kahler's Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the...

Multiple Myeloma: Your Way Forward
by Abaco Publishing

You will never cure anything if you don’t do something about the underlying cause. This applies to every illness including multiple myeloma. In my book ‘Multiple Myeloma – Your way forward’ I explain why it may have developed, giving you something to do to change the underlying causes and bring things under control. It is most likely to be a virus that your immune system has failed to eliminate, but it could also be bad eating habits, a poor immune system, infections, too many antibiotics, toxic chemicals, geopathic stress and certainly stresses of everyday life affecting your emotions. When cancer declares itself, it could have been developing for ten or fifteen years. All of this is explained to you in detail as though you are with me in my consulting room. I then give ideas on...

Multiple Myeloma: A Textbook for Nurses
by Joseph A. Tariman (Author)

Since the advent of novel chemotherapeutic agents in the 2000s, patients with multiple myeloma have experienced an improvement in clinical outcomes and better quality of life. However, with these new agents, patients have also experienced clinical challenges and side effects that, until now, have not been accurately described. Multiple Myeloma: A Textbook for Nurses, edited by Joseph D. Tariman, PHC, MN, APRN-BC, OCNÂ®, is the first book on multiple myeloma written by nurses for nurses. You ll discover the meaning of multiple myeloma as well as a history of the disease, including nursing contributions to myeloma care. You ll also gain an understanding of basic anatomy and physiology, the role genetics plays in patients with this disease, and you ll look at incidence rates and risk...

Multiple Myeloma and Related Serum Protein Disorders: An Electrophoretic Guide
by Neil Harris MD (Author), William Winter MD (Author)

Multiple Myeloma and Related Serum Protein Disorders is a practical guide to the clinical use of serum and urine electrophoresis and also includes coverage of immunofixation electrophoresis. These techniques are essential in the accurate identification of monoclonal gammopathies and the diagnosis of multiple myeloma and related disorders. Interpretation is often challenging even for the experienced practitioner. . Throughout the book the emphasis is on indications and practical aspects of interpreting test results. Particular attention is paid to differentiating false negative and false positive test results. The text provides clear, practical discussions extensively supported by representative images to guide the reader to accurate identification of specimens. Multiple Myeloma and...

Contemporary Management of Multiple Myeloma
by Ravi, M.D. Vij (Author), Shaji K., M.D. Kumar (Foreword)

Extensive discussion of the science of multiple myeloma, including the epidemiology, pathophysiology diagnosis, new diagnostic and prognostic criteria and various treatment options.